Autifony Therapeutics initiates a Phase I study of its novel Kv3 modulator for schizophrenia and hearing disorders

BY      |     May 4, 2020

Autifony Therapeutics, a biotechnology company developing novel treatments for serious disorders of the central nervous system, announced that a First-in-Human, randomized, placebo controlled Phase I trial of AUT00201, a potent and selective modulator of Kv3 channels, is underway in the UK.

Kv3 channel dysfunctions have been implicated in a variety of CNS disorders. Autifony’s AUT00201 selectively modulates the function of Kv3 channels and restore normal neuronal function.

The trial has been suspended temporarily in response to the COVID-19 pandemic.

Read the press release here.

Read more about Autifony Therapeutics here.

Image by Gerd Altmann from Pixabay

Comments? Questions? Suggestions?

If you have any comments, questions or suggestions concerning this article, feel free to email me at
Alternatively, you can leave your comments on LinkedIn or Twitter.